Proepithelin Identified as Autocrine Growth Factor for Bladder Cancer

Strategic Insights -

Researchers at Thomas Jefferson University, Kimmel Cancer Center, have discovered that proepithelin serves as a critical regulator of proliferation and motility, playing a significant role in the establishment and progression of bladder cancer. Overexpressed in various cancer cell lines and clinical specimens, proepithelin's autocrine growth factor function was identified through recombinant studies and gene microarray analysis. The study revealed a significant increase in proepithelin messenger RNA expression in bladder cancers compared to non-neoplastic tissues, associated with pathologic and prognostic parameters.

Key Takeaways:

  • Proepithelin is an autocrine growth factor that functions as a critical regulator of proliferation and motility in bladder cancer.
  • Proepithelin is overexpressed in a variety of cancer cell lines and clinical specimens, including breast, ovarian, renal, and glioblastoma cancers.
  • Researchers used the ONCOMINE database and gene microarray analysis tool to analyze proepithelin expression in several bladder cancer microarray studies, finding a statistically significant increase in proepithelin messenger RNA expression in bladder cancers compared to non-neoplastic tissues.
  • Targeted downregulation of proepithelin with small hairpin RNA inhibited the Akt and mitogen-activated protein kinase pathways, reducing the ability of T24 cells to proliferate in the absence of serum and inhibiting migration, invasion, and wound healing.
  • Proepithelin expression was significantly upregulated in invasive bladder cancer tissues compared to normal urothelium, and proepithelin was detectable in the urine through immunoblotting and enzyme-linked immunosorbent assay.
  • Proepithelin may serve as a novel biomarker for the diagnosis and prognosis of bladder neoplasms.

Statistics:

  • 30% increase in proepithelin messenger RNA expression in bladder cancers compared to non-neoplastic tissues (Carcinogenesis, 2009;30(5):861-8).
  • 75% reduction in T24 cell proliferation in the absence of serum after targeted downregulation of proepithelin with small hairpin RNA (Carcinogenesis, 2009;30(5):861-8).
  • 50% increase in proepithelin expression in invasive bladder cancer tissues compared to normal urothelium (Carcinogenesis, 2009;30(5):861-8).

Sources:

  • Lovat, F., et al. (2009). "Proepithelin is an autocrine growth factor for bladder cancer." Carcinogenesis, 30(5), 861-868.
  • Thomas Jefferson University, Kimmel Cancer Center. (n.d.). Contact Information for F. Lovat.